Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug CandidatesReport as inadecuate


Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates


Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates - Download this document for free, or read online. Document in PDF available to download.

1

Wayne, PA 19087, USA

2

Gaithersburg, MD 20877, USA





*

Author to whom correspondence should be addressed.



Academic Editor: Keith B. Glaser

Abstract In this review, we have attempted to describe all of the antibody–drug conjugates using a marine-derived compound as the -warhead-, that are currently in clinical trials as listed in the current version of the NIH clinical trials database clinicaltrials.gov. In searching this database, we used the beta-test version currently available, as it permitted more specific search parameters, since the regular version did not always find trials that had been completed in the past with some agents. We also added small discussion sections on candidates that are still at the preclinical stage, including a derivative of diazonamide that has an unusual interaction with tubulin DZ-23840, which may also be a potential warhead in the future. View Full-Text

Keywords: Antibody Drug Conjugates ADCs; marine derived antitumor agents; clinical trials Antibody Drug Conjugates ADCs; marine derived antitumor agents; clinical trials





Author: David J. Newman 1,* and Gordon M. Cragg 2

Source: http://mdpi.com/



DOWNLOAD PDF




Related documents